The frameshift product (fsANP), but not wild-type ANP (wtANP), was elevated in the serum of affected patients, but the molecular basis for the elevated peptide concentrations was not determined. Here, we measured the ability of fsANP to interact with natriuretic peptide receptors and to be proteolytically degraded. fsANP and wtANP bound and activated human NPR-A and NPR-C similarly, whereas fsANP had a slightly increased efficacy for human NPR-B. Proteolytic susceptibility was addressed with novel bioassays that measure the time required for kidney membranes or purified neutral endopeptidase to abolish ANP-dependent activation of NPR-A. The half-life of fsANP was markedly greater than that of wtANP in both assays. Additional membrane proteolysis studies indicated that wtANP and fsANP are preferentially degraded by neutral endopeptidase and serine peptidases, respectively. These data indicate that the familial ANP mutation associated with atrial fibrillation has only minor effects on natriuretic peptide receptor interactions but markedly modifies peptide proteolysis.
Natriuretic peptides are pleiotropic factors that regulate blood pressure, cardiac hypertrophy, and long bone growth (1) . Humans express three family members, atrial natriuretic peptide (ANP), 3 B-type natriuretic peptide, and C-type natriuretic peptide (CNP). Each peptide is the product of a separate gene and contains a highly conserved 17-amino acid disulfide-linked ring structure that is required for biological activity. Atrial stretch causes ANP to be released from stored granules as a result of cardiovascular stresses like congestive heart failure. Once released into the circulation, ANP binds receptors in multiple tissues to reduce the load on the heart by stimulating natriuresis, diuresis, extravasation, vasorelaxation, and inhibiting the renin-angiotensin-aldosterone system (1) .
Natriuretic peptides exert their effects by binding one or more of three natriuretic peptide receptors. Natriuretic peptide receptor A (NPR-A) is the endogenous receptor for ANP and BNP (2, 3) . NPR-A is a transmembrane guanylyl cyclase that, upon ligand binding, synthesizes the second messenger cGMP that mediates the renal and vascular effects of ANP and BNP (4, 5) . Meanwhile, natriuretic peptide receptor B (NPR-B) is the receptor for CNP (6) . NPR-B is highly homologous to NPR-A and also possesses guanylyl cyclase activity. The primary ligand for NPR-B is CNP, but this receptor can also be activated by very high concentrations of ANP or BNP (6) . CNP-dependent activation of NPR-B stimulates long bone growth and may also inhibit cardiac hypertrophy (7) . The third natriuretic peptide receptor is natriuretic peptide receptor C (NPR-C). Unlike NPR-A and NPR-B, NPR-C does not contain a guanylyl cyclase domain (8) . Instead, the primary function of NPR-C is to control local natriuretic peptide concentrations through receptormediated internalization and degradation. Thus, it is typically referred to as the clearance receptor (9) . In addition to its role in clearing natriuretic peptides from the circulation, NPR-C has also been shown to signal in a G protein-dependent manner (10) . Finally, the other mechanism for natriuretic peptide removal is proteolytic degradation. Neutral endopeptidase (EC 3.4.24.11), which is also referred to as neprilysin or NEP, has been suggested to be the primary ANP-degrading enzyme in tissues associated with ANP clearance (11) (12) (13) . Furthermore, inhibitors of NEP have been shown to increase circulating concentrations of ANP in rats (14) .
In a recent New England Journal of Medicine article, Hodgson-Zingman et al. (15) investigated the genetic basis for early onset atrial fibrillation in a family with white European ancestry. Using linkage analysis they found that all affected family members contained a single allele with a frameshift mutation in the coding portion of the ANP gene. The mutation causes a two-base pair deletion in exon 3 that eliminates the original stop codon and causes 12 new amino acids to be appended to the C terminus of the mature peptide. Thus, the peptide resulting from the frameshift mutation (fsANP) consists of 40 amino acids, whereas the wild-type peptide (wtANP) consists of 28 amino acids (Fig. 1) . Importantly, the plasma levels of fsANP were shown to be 5-10-fold higher than the plasma concentrations of wtANP in affected individuals.
Although Hodgson-Zingman et al. elegantly identified the ANP mutation associated with patients with early onset atrial fibrillation, they did not determine how this mutation affects the ability of ANP to interact with its known biological partners or why this mutation leads to elevated peptide concentrations. Theoretically, modulated binding to NPR-A, NPR-B, or NPR-C or altered proteolytic processing of ANP could lead to the observed disease. In this report, we identified subtle differences in the ability of fsANP and wtANP to interact with natriuretic peptide receptors but major differences in the proteolytic degradation of these peptides.
EXPERIMENTAL PROCEDURES
Reagents-Human wild-type ANP and frameshift ANP (SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDK-QGWA) were synthesized and purified by AnaSpec, Inc. (San Jose, CA).
125 I-ANP and the 125 I-cGMP radioimmunoassay kits were from PerkinElmer Life Sciences. Purified recombinant human neprilysin (NEP) was from R & D Systems (Minneapolis, MN). Protease inhibitors were from Roche Applied Science (Complete protease inhibitor mixture tablet), MP Biomedicals, LLC (phosphoramidon), and Sigma (DL-thiorphan and leupeptin).
Cells-Human embryonic 293 cells lacking any known natriuretic peptide receptor (293neo) and stably expressing various human or rat natriuretic peptide receptors were maintained as previously described (16 -18) .
Whole Cell Stimulations-Whole cell stimulations were performed as described (16) . Briefly, cells plated on poly-D-lysinecoated 48-well plates were incubated overnight in serum-free medium upon reaching 50% confluency. Medium was aspirated, and 0.2 ml of DMEM containing 1 mM 1-methyl-3-isobutylxanthine (IBMX) and 25 mM Hepes, pH 7.4, was added and incubated for 10 min. Following pretreatment, the medium was aspirated, and the cells were treated with DMEM containing 1 mM IBMX and 25 mM Hepes, pH 7.4, with or without natriuretic peptide for 3 min. Treatment medium was then aspirated, and the reaction was stopped with 0.2 ml of ice-cold 80% ethanol. An aliquot of the resulting supernatant was dried in a centrifugal vacuum concentrator and analyzed for cGMP content by radioimmunoassay.
Guanylyl Cyclase Assays-Crude membranes were prepared and assayed as previously described (19) . Guanylyl cyclase assays were performed at 37°C for 3 min in a buffer containing 25 mM Hepes, pH 7.4, 50 mM NaCl, 0.1% bovine serum albumin, 0.5 mM IBMX, 1 mM GTP, 1 mM EDTA, 0.5 mM microcystin, 5 mM MgCl 2 in the presence or absence of increasing concentrations of the indicated natriuretic peptide. The reactions were initiated by the addition of the above reagents to 20 l of crude membranes and stopped by the addition of 0.4 ml of ice-cold 50 mM sodium acetate buffer containing 5 mM EDTA and placed on ice. Cyclic GMP concentrations were determined by radioimmunoassay.
Whole Cell Binding AssaysWhole cell binding assays were performed as previously described (16) . Briefly, cells in 24-well plates were washed with DMEM and then incubated with DMEM containing 0.2% bovine serum albumin at 37°C for 1-2 h. The medium was aspirated, and 0.2 ml of binding medium containing 75 pM 125 I-ANP and 1% bovine serum albumin, alone or with increasing concentrations of unlabeled ligand, was added to the cells. The plates were incubated at 4°C for 1 h before the binding medium was aspirated, and the cells were washed with 0.5 ml of ice-cold phosphate-buffered saline. The cells were solubilized in 0.5 ml of 1 N NaOH and transferred to glass tubes, and bound radioactivity was measured in a Beckman 5500 gamma counter.
Proteolysis Bioassay-Human kidney samples were obtained from the Tissue Procurement Program at the University of Minnesota and stored at Ϫ80°C until use. Crude membranes were prepared using a modification of the previously published protocol (20) . Briefly, the membranes were prepared in a modified buffer lacking protease inhibitors (50 mM Tris-HCl, pH 7.5, 20% glycerol, 50 mM NaF) and stored at Ϫ80°C. For proteolysis, an aliquot of membranes was thawed and diluted to 2 mg/ml with ice-cold buffer. The reaction was started with the addition of 40 g crude membranes to a solution containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM Mg 2 Cl, 0.1% bovine serum albumin, and 1 M natriuretic peptide and incubated for the indicated period of time at 37°C. The reactions were terminated by addition of 100 l of 0.5 N perchloric acid. The samples were neutralized with 5 l of 10 N NaOH before centrifugation for 5 min at 20,000 ϫ g at 4°C. An aliquot of the supernatant was mixed with DMEM containing 1 mM IBMX and 25 mM Hepes and then added to cells stably expressing human NPR-A for 3 min at 37°C to determine peptide bioactivity. The stimulation reaction was stopped by adding 0.3 ml of 0.1 N HCl. Aliquots of the acid extracts were neutralized with NaOH and then subsequently assayed for cGMP content by radioimmunoassay.
Statistical Analysis-All of the statistical analyses were performed with GraphPad Prism software. Whole cell stimulation, guanylyl cyclase, and binding data were analyzed using a nonlinear regression model. Proteolytic half-lives were determined using a one-site exponential decay model. For the proteolysis experiments, cGMP values from the bioassay were converted to nanomoles peptide according to peptide standard concentration response curves performed with each bioassay. These pep- tide concentrations were then converted to percent control (zero time) peptide so both ANP and fsANP could be graphed on the same scale. All p values were obtained using a paired t test.
RESULTS
fsANP Binding and Activation of Human NPR-A-We initially evaluated the ability of fsANP to bind and activate human NPR-A, the receptor responsible for mediating most physiologic effects of ANP and BNP. Using a whole cell competitive binding assay, the affinity of fsANP for human NPR-A was examined. A specific line of 293 cells stably expressing the human form of NPR-A but no other natriuretic peptide receptor was used for these studies (16) . Importantly, these cells do not possess significant extracellular ANP degrading activity (data not shown). Thus, because the cellular system does not express endogenous natriuretic peptide receptors or natriuretic peptide degrading activities, we could unequivocally attribute 125 I-ANP binding to human NPR-A in this assay. To determine binding affinity, increasing levels of unlabeled fsANP or wtANP were included to competitively reduce 125 I-ANP binding to NPR-A. The concentrations of peptide required to inhibit 50% of the specific binding (IC 50 ) were 1.6 and 2.4 nM for wtANP and fsANP, respectively, which were not statistically significantly different ( Fig. 2A) .
To compare the ability of the peptides to activate the guanylyl cyclase activity of human NPR-A, the same cells were incubated with increasing concentrations of either fsANP or wtANP and the formation of intracellular cGMP was measured. The concentration-response curves for wtANP and fsANP yielded EC 50 values of 12.5 and 11.6 nM, respectively (Fig. 2B) . Again, these values were not statistically different from one another. The maximal activation of human NPR-A achieved with ANP was slightly but not significantly higher than that observed with fsANP. The ability of fsANP and wtANP to stimulate endogenous human NPR-A in HeLa cells was also not different (data not shown). To directly assess NPR-A activation, hormone-dependent guanylyl cyclase activity was measured on crude membrane preparations from 293 cells stably expressing human NPR-A. As shown in Fig. 2C , the potency of fsANP and wtANP was identical in this assay at every concentration except 10 M. However, at the highest concentration, fsANP resulted in a statistically significant higher level of intracellular cGMP concentrations than wtANP. Based on these three assays, we conclude that fsANP and wtANP bind and activate human NPR-A similarly, although maximum activation of NPR-A in a broken cell assay was slightly greater with fsANP.
Reduced Potency of fsANP for Rat NPR-A-Because the initial report describing the ANP frameshift mutation used a rat model to illustrate effects of this peptide on atrial action potential duration, we compared the ability of fsANP and human wtANP to activate the rat version of NPR-A. Cells specifically expressing rat NPR-A were incubated with increasing concentrations of fsANP or wtANP, and whole cell cGMP accumulation was measured by radioimmunoassay (Fig. 3A) . The effective concentrations required to elicit 50% of the maximum cGMP concentrations were 18 and 55 nM for wtANP and fsANP, respectively (p ϭ 0.02). This represents a 3-fold decrease in potency of fsANP as compared with wtANP. As with human NPR-A, 125 I-ANP was used to assess affinity to rat NPR-A via competition binding assays. The IC 50 values for rat ANP, human wtANP, or human fsANP binding to rat NPR-A were 5, 37, and 77 nM, respectively (Fig. 3B) . When compared with human ANP, fsANP results in roughly a 2-fold decrease in binding affinity (p ϭ 0.001). Therefore, reduced potency of fsANP to the rat receptor results, at least in part, from diminished receptor binding. However, the significance of this finding is unclear because the reduced affinity and potency of fsANP for rat NPR-A is very small and is undetectable for the human receptor.
fsANP Causes Slightly Greater cGMP Accumulations in Cells Expressing Human NPR-B-Because we recently reported that relatively subtle changes in the sequence of natriuretic peptides can increase affinity for related receptors (16), we examined the ability of fsANP to activate human NPR-B. Cells specifically expressing human NPR-B were stimulated with increasing concentrations of fsANP, wtANP, or its cognate ligand CNP, and intracellular cGMP accumulation was measured by radioimmunoassay (Fig. 4A) . The EC 50 values obtained for fsANP, wtANP, and CNP were 800, 1200, and 8 nM, respectively. The EC 50 values for fsANP and wtANP were statistically significantly different (p ϭ 0.01). Additionally, the maximum activity obtained with fsANP was 50% greater than that obtained with wtANP (p ϭ 0.025). In contrast, when crude membrane preparations of 293neo-hNPR-B cells were used to assess the ability of fsANP or wtANP to directly stimulate NPR-B guanylyl cyclase activity versus the whole cell assay, the activation of NPR-B by fsANP or wtANP was not significantly different (Fig. 4B) .
fsANP Binding to Human NPR-C-Hodgson-Zingman et al. (15) reported that plasma levels of fsANP were much higher than wtANP concentrations. Therefore, we examined whether fsANP had a reduced ability to bind human NPR-C, the main in vivo pathway for clearing circulating natriuretic peptides (21) . By performing competition 125 I-ANP binding assays on 293 cells stably expressing NPR-C, the affinity of fsANP and wtANP for NPR-C was determined (Fig. 5) . The concentrations of peptide needed to inhibit 50% of specific binding to NPR-C, 2.4 and 3.2 nM for wtANP and fsANP, respectively, were almost identical. Thus, we conclude that fsANP and wtANP bind NPR-C similarly.
fsANP Is Resistant to Proteolysis by Human Renal PeptidasesIn addition to clearance by NPR-C, degradation of ANP occurs through the actions of luminal vessel peptidases. The most studied protease in this regard is NEP (22, 23) . NEP cleaves the Cys 7 -Phe 8 bond just inside the ring of the 28-amino acid form of ANP (24) , resulting in the loss of biological activity. Studies have shown that inhibiting NEP results in a longer half-life both in vitro (13, 22) and in vivo (25) , which suggests that NEP activity contributes to the rapid clearance of ANP. However, mice lacking NEP do not display characteristics of natriuretic peptide excess like hypotension and giantism that are observed in mice lacking NPR-C (9). Therefore, it is likely that other peptidases degrade natriuretic peptides as well (27) .
Because fsANP levels are elevated in patients with the defective allele and because fsANP had no effect on NPR-C binding, we examined the possibility that the 12-amino acid addition to ANP confers resistance to proteolytic degradation. To investigate this possibility, we developed a novel bioassay that measures the ability of human kidney membranes to proteolytically inactivate natriuretic peptides. The assay has two stages. First, fsANP or wtANP were incubated with kidney membranes to allow enzymatic peptide degradation. We used human kidney membranes because the kidney is a major clearance organ for ANP, and the kidney is known to contain many ANP degrading peptidases (28, 29) . Proteolysis was terminated with the addition of perchloric acid because these conditions denature most proteins without affecting the biologic activity of natriuretic peptides. The bioactivity of the neutralized extracts was subsequently evaluated in the second stage of the assay by measuring its ability to stimulate cGMP elevations in 293 cells specifically expressing human NPR-A.
Using a one-site exponential decay model, this assay demonstrated that the half-life of fsANP (4.5 min) was nearly twice as long as that of wtANP (2.6 min) (Fig. 6A) . Importantly, control experiments demonstrated that peptide inactivation was blocked by boiling the membranes or by including protease inhibitors during the degradation stage (Fig. 6B) . Surprisingly, we found that ANP degradation was preferentially blocked by the NEP-specific inhibitors phosphoramidon or DL-thiorphan, whereas fsANP degradation was more sensitive to inhibition by leupeptin, a serine protease inhibitor. The incomplete inhibition of fsANP degradation by boiling of the kidney membranes was variable because some membrane preparations were completely inactivated by boiling and others were not. Thus, the addition of the 12 C-terminal amino acids to ANP increases the half-life of the peptide by reducing proteolysis and changing the proteolytic degradation profile.
The ability of purified recombinant human NEP to degrade fsANP and wtANP was also measured. NEP caused a total loss of wtANP activity, which was essentially complete by 30 min (Fig. 7A) . In contrast, NEP only reduced fsANP activity by ϳ35% after 30 min, and no significant further decline was observed after 2 h. As anticipated, NEP-dependent degradation of wtANP was blocked by the NEP inhibitors phosphoramidon and thiorphan (Fig. 7B) . Interestingly, neither boiling NEP nor incubating the enzyme with specific NEP inhibitors had any effect on the ability of the purified enzyme preparation to reduce fsANP activity, whereas a broad spectrum protease inhibitor mixture slightly blocked the reduction in activity observed with the purified enzyme preparation. These data are unexpected. However, they can be explained if the purified NEP preparation was contaminated by a second heat-resistant protease that completely cleaves fsANP outside the disulfide ring and that is blocked by broad range inhibitors. Regardless, these where n ϭ 9. The p value was Ͼ 0.05. FIGURE 6. fsANP is resistant to protease-dependent degradation and has a different protease susceptibility profile than wtANP. A shows the ability of human kidney membranes to degrade wt or fsANP. 1 M concentrations of each peptide were incubated with 40 g of human kidney membranes for the designated periods of time at 37°C in a total volume of 0.1 ml. Proteolysis was terminated by addition of 0.1 ml of 0.5 M perchloric acid, and bioactivity was evaluated by measuring the ability of the neutralized extracts to elevate cGMP concentration in HEK 293 cells stably expressing human NPR-A. The error bars represent the S.E. where n ϭ 4. B shows the effect of blocking human kidney membrane-dependent degradation of wt or fsANP peptide by boiling the membranes for 30 min prior to exposure to peptide or by including various protease inhibitors in the proteolysis assay. Each point represents the mean Ϯ S.E. where n ϭ 12.
data clearly indicate that the 12-amino acid extension resulting from the frameshift mutation dramatically reduces the ability of ANP to be degraded by NEP.
DISCUSSION
This study comprehensively examined the functional consequences of the frameshift mutation of ANP that was recently identified in patients with familial atrial fibrillation (15) . In our experiments, the ability of fsANP to activate and bind human natriuretic peptide receptors was very similar to that of wtANP. However, subtle differences were identified in the ability of the mutant and wild-type peptides to activate human NPR-B. In one experimental protocol, whole cell activation yielded a statistically significant difference, whereas another protocol, a broken membrane guanylyl cyclase assay, indicated no significant difference between the ability of fsANP and wtANP to activate human NPR-B. One possible explanation for the difference between the whole cell and broken cell assays is that an intracellular protease is degrading ANP in the later assay. We can only speculate as to what contribution, if any, this receptor effect makes on the disease process, especially given the high concentrations required for activation of NPR-B. However, because decades are required for clinical symptoms of the disease to become apparent, even minor effects could result in significant disease manifestation if given enough time.
In contrast to the speculative receptor effects, the consequences of the mutation on ANP proteolysis is dramatic. fsANP was much more resistant to inactivating proteolysis than wtANP, which is in complete agreement with the elevated fsANP, but not wtANP, levels observed in patients with the mutant allele. Additionally, fsANP was inactivated by a different class of protease compared with wtANP. NEP is widely reported as the ANP-degrading enzyme. Indeed, we also observed that purified human NEP completely inactivates (degrades) wtANP. In contrast, fsANP was resistant to complete inactivation by NEP but demonstrated a partial reduction in activity. The partial inactivation by NEP that is not affected by time suggests that fsANP is being degraded to a peptide that is a less potent receptor agonist; this is in contrast to wtANP, which is degraded to a peptide that is no longer an NPR-A receptor agonist. The inability of the NEP-specific protease inhibitors, phosphoramidone and DL-thiorphan, to block the degradation of fsANP by NEP suggests that NEP is not involved in this degradation but that a contaminating enzyme in the NEP preparation is responsible for the degradation. Preboiling NEP also had little effect on the subsequent degradation of fsANP. Because the control sample was prepared in the same sample assay and enzyme dilution buffers, a contaminant in the original NEP sample is a reasonable explanation for the degradation of fsANP in the NEP experiments. Interestingly, when using human kidney samples, fsANP was completely degraded by 30 min. Thus, either the contaminant in the NEP sample is not present in the kidney samples, or there is an additional enzyme in the kidney samples that is able to further degrade the fsANP partial agonist to an inactive form. However, please note that the human kidney samples used in our assays were from patients with kidney disease. Various disease states change the protease profile of the kidney samples, which may contribute to the partial inhibition of wtANP degradation by NEP-specific inhibitors seen in our experiments (Fig. 6 ) versus complete inhibition in previous reports. For example, severe heart failure has been reported to increase expression of renal NEP (30), whereas atrial fibrillation decreases expression of NEP (31) . We also observed variation in the ability of each membrane preparation to degrade wtANP or fsANP. However, the data shown in Fig. 6 is representative of all samples assayed in that wtANP is more susceptible to degradation by NEP than fsANP, whereas fsANP is most susceptible to degradation by a serine protease(s). Future experiments will focus on determining the site of cleavage of fsANP and the serine protease that mediates this inactivation. Nonetheless, the 12-amino acid C-terminal extension results in decreased NEP-dependent ANP degradation, which ultimately increases the half-life of the circulating peptide.
The main functional difference for fsANP described by Hodgson-Zingman et al. (15) in the original report was that fsANP decreased the monophasic action potential or effective refractory period in a rat hanging heart model. Knowing that activation of human and rat NPR-A is not always equivalent, we measured the effect of the 12-amino acid extended form of ANP on rat NPR-A versus wt (human) ANP and found a 3-fold decrease in potency and a 2-fold decrease in binding affinity. wtANP perfusion did not change the monophasic action potential or effective refractory period in the rat hanging heart model, which is reasonable because this is a denervated preparation (15) . However, fsANP did decrease the parameters in a relatively short 40-min infusion protocol. Based on the decrease in potency and binding affinity of fsANP versus wtANP to rat natriuretic peptide receptors in our studies, it is hard to understand how fsANP and wtANP could have differential responses in the rat hanging heart model. However, it is possible that fsANP elicits a more sustained response in this assay because of reduced proteolytic degradation.
The monophasic action potential and effective refractory period of the heart are highly regulated because they control atrial pacing. Decreases in the monophasic action potential and effective refractory period result in faster atrial contractions. When regulation of atrial conduction is disrupted or fails, then atrial fibrillation can occur. Exogenous ANP treatment has been shown to shorten atrial conduction time as well as the effective refractory period in intact human hearts (32) . Additional studies in anesthetized canines demonstrated that ANPdependent decreases in monophasic action potential and effective refractory period are due to secondary autonomically mediated effects (33) . Another study demonstrated that these vagal reflexes can be activated both by ANP infusion and by inhibiting its degradation by blocking NEP (26) . The implication from the Hodgson-Zingman study is that in patients expressing fsANP, these vagal reflexes would be under more prolonged pressure because of the elevated levels of total ANP (wtANP ϩ fsANP), which would eventually lead to early onset atrial fibrillation. Whether the changes in proteolysis and halflife of fsANP are enough to cause the elevated serum levels of fsANP and whether those elevated serum levels (36 pM) are high enough to physiologically affect the monophasic action potential as assayed by Hodgson-Zingman et al. (15) at 100 nM are not known. Given the length of time for clinical symptoms to develop, one might speculate that it is the long term consequences of elevated (5-10 times wtANP plasma levels) fsANP that ultimately leads to early onset atrial fibrillation. Furthermore, the regulation of peptide activity in vivo could be compounded in disease conditions in which the protease profile is altered.
Finally, in contrast to the deleterious effects of long term exposure to fsANP, the short term effects of C-terminal extensions of natriuretic peptides may be significant for the development of longer acting drugs. One of the problems facing developers of designer natriuretic peptides is their relatively short half-life in vivo. For instance, the in vivo half-life of ANP is only 2 min, making it necessary to continuously administer ANP intravenously. Increasing the half-life of natriuretic peptidebased drugs could facilitate subcutaneous or alternative administration options as well as reduce the total peptide dose.
